RIGL Rigel Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RIGL

Price (delayed)

$1.06

Market cap

$184.83M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.14

Enterprise value

$200.22M

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare ...

Highlights
Rigel Pharmaceuticals's EPS has surged by 71% YoY and by 36% QoQ
The net income has surged by 70% year-on-year and by 35% since the previous quarter
RIGL's equity has plunged by 61% YoY and by 13% from the previous quarter
RIGL's debt is up by 42% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.rigel.com
Peers: SGMO AMGN XOMA

Key stats

What are the main financial stats of RIGL
Market
Shares outstanding
174.37M
Market cap
$184.83M
Enterprise value
$200.22M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.51
Earnings
Revenue
$132.37M
EBIT
-$18.36M
EBITDA
-$17.13M
Free cash flow
-$20.99M
Per share
EPS
-$0.14
Free cash flow per share
-$0.12
Book value per share
-$0.18
Revenue per share
$0.76
TBVPS
$0.58
Balance sheet
Total assets
$115.32M
Total liabilities
$147.16M
Debt
$60.8M
Equity
-$31.83M
Working capital
$46.75M
Liquidity
Debt to equity
-1.91
Current ratio
1.97
Quick ratio
1.78
Net debt/EBITDA
-0.9
Margins
EBITDA margin
-12.9%
Gross margin
97.2%
Net margin
-18.5%
Operating margin
-15.4%
Efficiency
Return on assets
-19.9%
Return on equity
N/A
Return on invested capital
-25%
Return on capital employed
-27.4%
Return on sales
-13.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RIGL stock price

How has the Rigel Pharmaceuticals stock price performed over time
Intraday
3.92%
1 week
11.57%
1 month
45.17%
1 year
51.45%
YTD
-29.33%
QTD
-1.85%

Financial performance

How have Rigel Pharmaceuticals's revenue and profit performed over time
Revenue
$132.37M
Gross profit
$128.71M
Operating income
-$20.38M
Net income
-$24.43M
Gross margin
97.2%
Net margin
-18.5%
The operating margin has soared by 83% YoY and by 43% from the previous quarter
RIGL's net margin has soared by 80% YoY and by 38% QoQ
RIGL's operating income has surged by 74% year-on-year and by 41% since the previous quarter
The net income has surged by 70% year-on-year and by 35% since the previous quarter

Growth

What is Rigel Pharmaceuticals's growth rate over time

Valuation

What is Rigel Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
1.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.51
Rigel Pharmaceuticals's EPS has surged by 71% YoY and by 36% QoQ
RIGL's equity has plunged by 61% YoY and by 13% from the previous quarter
The stock's price to sales (P/S) is 67% less than its 5-year quarterly average of 4.1 and 26% less than its last 4 quarters average of 1.8
Rigel Pharmaceuticals's revenue has increased by 48% YoY and by 4.5% QoQ

Efficiency

How efficient is Rigel Pharmaceuticals business performance
Rigel Pharmaceuticals's return on sales has surged by 84% YoY and by 46% QoQ
RIGL's return on invested capital has surged by 70% year-on-year and by 41% since the previous quarter
The return on assets has surged by 66% year-on-year and by 35% since the previous quarter

Dividends

What is RIGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RIGL.

Financial health

How did Rigel Pharmaceuticals financials performed over time
Rigel Pharmaceuticals's total assets is 22% less than its total liabilities
RIGL's current ratio is down by 16% year-on-year and by 14% since the previous quarter
The quick ratio has contracted by 14% YoY and by 8% from the previous quarter
RIGL's equity has plunged by 61% YoY and by 13% from the previous quarter
RIGL's debt is up by 42% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.